# A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)

> **NCT07717840** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 164 (actual)

## Conditions studied

- RSV Respiratory Syncytial Virus

## Interventions

- **BIOLOGICAL:** AZD6489
- **BIOLOGICAL:** Licensed RSV vaccine #1
- **BIOLOGICAL:** Licensed RSV vaccine #2

## Key facts

- **NCT ID:** NCT07717840
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-07-08
- **Primary completion:** 2026-10-07
- **Final completion:** 2027-08-19
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2026-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07717840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07717840, "A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07717840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*